Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;128(3):301-303.
doi: 10.1111/bju.15485. Epub 2021 Jun 4.

Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579)

Sophie Knipper  1 , Derya Tilki  1   2 , Markus Graefen  1 , Tobias Maurer  1   2
Affiliations

Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579)

Sophie Knipper et al. BJU Int. 2021 Sep.
No abstract available

PubMed Disclaimer

Comment in

References

    1. Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016; 13: 226-35
    1. Perera M, Papa N, Roberts M et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2020; 77: 403-17
    1. EAU Guidelines. Edn. Presented at the EAU Annual Congress Amsterdam 2020. ISBN 978-94-92671-07-3. [Internet]. Uroweb. Available at: https://uroweb.org/guideline/prostate-cancer/#11. Accessed April 2020
    1. Steuber T, Jilg C, Tennstedt P et al. Standard of care versus metastases-directed therapy for PET-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus 2019; 5: 1007-13
    1. Maurer T, Robu S, Schottelius M et al. 99mTechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol 2019; 75: 659-66

MeSH terms

LinkOut - more resources